礼来 | 全球首个“OSA治疗药物”替尔泊肽注射液“穆峰达®”正式获批

生物科技馆
05 Jul

2025年6月30日,礼来(LLY.US)公司自主要发的穆峰达®替尔泊肽注射液"用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停"适应症正式获国家药监局批准,也是穆峰达®在国内获批的第3个适应症。据悉,穆峰达®作为目前首个且唯一用于治疗OSA的处方药,可以改善中度至重度阻塞性睡眠呼吸暂停肥胖成人患者的睡眠障碍,但是使用需在控制饮食和增加运动基础上进行。根据临床试验结果显示,接受替尔泊肽治疗的患者...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10